Xenon Pharmaceuticals (XENE) Non-Current Debt (2017 - 2019)
Xenon Pharmaceuticals (XENE) posted quarterly Non-Current Debt of $10.9 million for Q4 2019, down 27.47% year-over-year from $15.0 million in Q4 2018, and down 7.61% quarter-over-quarter from $11.8 million in Q3 2019.
Xenon Pharmaceuticals (XENE) Non-Current Debt (2017 - 2019) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Non-Current Debt for 3 consecutive years, with $10.9 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Non-Current Debt fell 27.47% year-over-year to $10.9 million; the TTM figure through Dec 2019 stood at $10.9 million (down 27.47% YoY), while the FY2019 annual figure was $10.9 million, down 27.47% from the prior year.
- Non-Current Debt declined to $10.9 million in Q4 2019 per XENE's latest filing, from $11.8 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $15.1 million in Q1 2019 and bottomed at $5.5 million in Q1 2018.
- Historically, Non-Current Debt has averaged $11.6 million across 3 years, with a median of $11.8 million in 2019.
- On a YoY basis, Non-Current Debt climbed as much as 176.46% in 2019 and fell as far as 27.47% in 2019.
- Xenon Pharmaceuticals' Non-Current Debt stood at $6.1 million in 2017, then soared by 145.97% to $15.0 million in 2018, then decreased by 27.47% to $10.9 million in 2019.
- Business Quant data shows XENE's Non-Current Debt at $10.9 million in Q4 2019, $11.8 million in Q3 2019, and $13.2 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 10.89 Mn |
| Sep 30, 2019 | 11.79 Mn |
| Jun 30, 2019 | 13.20 Mn |
| Mar 31, 2019 | 15.14 Mn |
| Dec 31, 2018 | 15.01 Mn |
| Sep 30, 2018 | 14.89 Mn |
| Jun 30, 2018 | 11.72 Mn |
| Mar 31, 2018 | 5.48 Mn |
| Dec 31, 2017 | 6.10 Mn |